Genflow Biosciences Company
Genflow Biosciences research ways to work with the SIRT6 gene that is recognized as a master regulator of healthy aging. SIRT6 overexpression has been shown to lead to a healthy lifespan extension in both male and female mice. Genflow Biosciences intends to promote healthy aging by providing extra copies of a variant of the Human SIRT6 gene found in centenarians. Genflow Biosciences is developing an ethical, safe and efficient gene delivery system to deliver this centenarian variant of the SIRT6 gene.
Industry:
Biotechnology, Gene therapy
Headquarters:
Cambridge, Massachusetts, United States
Founded Date:
2020
Employees Number:
1-10
Funding Status:
Seed
Investors Number:
1
Last Funding Date:
Jan 15, 2021
Last Funding Type:
seed round
Register and Claim Ownership